Eli Lilly and Company (LLY)
NYSE
Healthcare
Drug Manufacturers - General
$1103.68
▲ +0.47%
Market Cap
$1.04T
Sector
Healthcare
Industry
Drug Manufacturers - General
Beta
0.52
52-Wk Range
623.78-1182.73
CEO
David A. Ricks
Country
US
Currency
USD
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In…
Open full interactive analysis & DCF →